Recent Episodes
Watch recent episodes on
The Financial Channel
Scroll Left
Scroll Right
ValiRx Plc: Financial Results




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: ValiRx Plc: Financial Results
Released on: July 31, 2008. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this Financial Report, the top Executives of ValiRx discuss their latest Financial Results, explain how they maintain shareholder value in spite of losses and hits on its share prices – a challenge faced in the global biotech industry – and its strategic course to continue to develop an R&D program which ensures future return for its investors.
  • Summary
  • Company
In this Financial Report, the top Executives of ValiRx discuss their latest Financial Results, explain how they maintain shareholder value in spite of losses and hits on its share prices – a challenge faced in the global biotech industry – and its strategic course to continue to develop an R&D program which ensures future return for its investors. Several new and exciting products are discussed including GeneICE and Vali101, and the executives explain the strategy they employ to both balance the cost of developing these drugs and hedging their risks to ensure early return to investors
ValiRx plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.